Nintedanib (BIBF 1120) in the treatment of solid cancers : an overview of biological and clinical aspects
Angiogenesis is essential for tumor growth and metastasis. The main regulators of the process are the signaling cascades of VEGF-, PDGF- and FGF receptors. Inhibition of these pathways holds potential therapeutic benefit not only for cancer patients, but also for the treatment of other diseases. This paper summarizes the experimental and clinical results of studies available so far on the multi-target tyrosine kinase inhibitor nintedanib (BIBF 1120). According to these studies, nintedanib effectively inhibits VEGFR-, PDGFR- and FGFR signalization and thus the proliferation and survival of cell types which highly express these receptors (i.e. endothelial and smooth muscle cells and pericytes). In vitro studies and in vivo xenograft experiments have provided promising results. In the clinical setting, BIBF 1120 seems to be effective and well tolerated in various tumor types, such as lung, prostate, colorectal and hepatocellular carcinoma, as well as in gynecological tumors. The main adverse events are gastrointestinal toxicities and the reversible elevation of liver enzyme levels. Nintedanib might also be combined with paclitaxel, carboplatin, pemetrexed and docetaxel. There are several ongoing clinical trials testing the efficacy of BIBF 1120.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Magyar onkologia - 56(2012), 3 vom: 07. Sept., Seite 199-208 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Nintedanib (BIBF 1120) a szolid daganatok kezelésében: biológia és klinikai tapasztalatok áttekintése |
|---|
| Beteiligte Personen: |
Török, Szilvia [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 27.02.2013 Date Revised 25.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM221306951 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM221306951 | ||
| 003 | DE-627 | ||
| 005 | 20231224051535.0 | ||
| 007 | tu | ||
| 008 | 231224s2012 xx ||||| 00| ||hun c | ||
| 028 | 5 | 2 | |a pubmed24n0737.xml |
| 035 | |a (DE-627)NLM221306951 | ||
| 035 | |a (NLM)23008829 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Török, Szilvia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nintedanib (BIBF 1120) in the treatment of solid cancers |b an overview of biological and clinical aspects |
| 246 | 3 | 3 | |a Nintedanib (BIBF 1120) a szolid daganatok kezelésében: biológia és klinikai tapasztalatok áttekintése |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2013 | ||
| 500 | |a Date Revised 25.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Angiogenesis is essential for tumor growth and metastasis. The main regulators of the process are the signaling cascades of VEGF-, PDGF- and FGF receptors. Inhibition of these pathways holds potential therapeutic benefit not only for cancer patients, but also for the treatment of other diseases. This paper summarizes the experimental and clinical results of studies available so far on the multi-target tyrosine kinase inhibitor nintedanib (BIBF 1120). According to these studies, nintedanib effectively inhibits VEGFR-, PDGFR- and FGFR signalization and thus the proliferation and survival of cell types which highly express these receptors (i.e. endothelial and smooth muscle cells and pericytes). In vitro studies and in vivo xenograft experiments have provided promising results. In the clinical setting, BIBF 1120 seems to be effective and well tolerated in various tumor types, such as lung, prostate, colorectal and hepatocellular carcinoma, as well as in gynecological tumors. The main adverse events are gastrointestinal toxicities and the reversible elevation of liver enzyme levels. Nintedanib might also be combined with paclitaxel, carboplatin, pemetrexed and docetaxel. There are several ongoing clinical trials testing the efficacy of BIBF 1120 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Benzenesulfonates |2 NLM | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Imidazoles |2 NLM | |
| 650 | 7 | |a Indazoles |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 650 | 7 | |a Oligonucleotides |2 NLM | |
| 650 | 7 | |a Phenylurea Compounds |2 NLM | |
| 650 | 7 | |a Phthalazines |2 NLM | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Quinazolines |2 NLM | |
| 650 | 7 | |a Receptors, Fibroblast Growth Factor |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a Niacinamide |2 NLM | |
| 650 | 7 | |a 25X51I8RD4 |2 NLM | |
| 650 | 7 | |a vatalanib |2 NLM | |
| 650 | 7 | |a 5DX9U76296 |2 NLM | |
| 650 | 7 | |a pazopanib |2 NLM | |
| 650 | 7 | |a 7RN5DR86CK |2 NLM | |
| 650 | 7 | |a Sorafenib |2 NLM | |
| 650 | 7 | |a 9ZOQ3TZI87 |2 NLM | |
| 650 | 7 | |a Axitinib |2 NLM | |
| 650 | 7 | |a C9LVQ0YUXG |2 NLM | |
| 650 | 7 | |a Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptors, Platelet-Derived Growth Factor |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptors, Vascular Endothelial Growth Factor |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a imetelstat |2 NLM | |
| 650 | 7 | |a F60NE4XB53 |2 NLM | |
| 650 | 7 | |a nintedanib |2 NLM | |
| 650 | 7 | |a G6HRD2P839 |2 NLM | |
| 650 | 7 | |a cediranib |2 NLM | |
| 650 | 7 | |a NQU9IPY4K9 |2 NLM | |
| 650 | 7 | |a vandetanib |2 NLM | |
| 650 | 7 | |a YO460OQ37K |2 NLM | |
| 700 | 1 | |a Cserepes T, Mihály |e verfasserin |4 aut | |
| 700 | 1 | |a Rényi-Vámos, Ferenc |e verfasserin |4 aut | |
| 700 | 1 | |a Döme, Balázs |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Magyar onkologia |d 1961 |g 56(2012), 3 vom: 07. Sept., Seite 199-208 |w (DE-627)NLM092654185 |x 2060-0399 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2012 |g number:3 |g day:07 |g month:09 |g pages:199-208 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2012 |e 3 |b 07 |c 09 |h 199-208 | ||